Aerie Pharmaceuticals Inc (NASDAQ:AERI) skyrocketed over 93% in pre-market trading up to $34.85 after the pharmaceutical company reported positive data for its second Phase 3 trial for Rhopressa. The pipeline drug is an eye drop intended to treat intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial successfully achieved its primary efficacy endpoint. As a result, several analysts reiterated their bullish sentiments on the company including Serge Belanger of Needham, who reiterated a Buy rating and boosted his price target from $27 to $45. The analyst notes that the company will proceed with a New Drug Application for the pipeline product. He concluded, “Based on ROCKET-1 and -2 results, Rhopressa, with its novel triple mechanism of action, looks well positioned to become the first new glaucoma treatment in over 20 years.” As of this writing, all 5 analysts polled by TipRanks in the last 3 months are bullish on AERI with an average 12-month price target of $41.40.

Click here to view Serge Belanger’s past rating history and performance.

Seadrill Ltd (NYSE:SDRL) slipped 3.33% in pre-market trading down to $7.25 this morning after oil prices pulled back, losing some of the gains the industry had last week. The public is growing antsy and wary while awaiting the Fed’s decision on hiking interest rates. The Federal Reserve’s interest rates have remain untouched for ten years as the institution allowed the U.S. to enjoy the unchanged rates as it recovered from the 2008 financial recession. Now that the economy has returned to pre-recession levels, the Fed is sitting in meetings discussing the potential rate hike. Low interest rates make commodities such as oil and gold attractive buys because they retain value, while higher interest rates discourage investing in commodities. According to TipRanks, both analysts who have weighed in on the oil giant in the past 3 months are bearish on the stock.

Oracle Corporation (NYSE:ORCL) slipped 2.5% this morning down to $37.31 after the company posted fiscal first-quarter earnings yesterday afternoon that revealed a decline in profits. The company posted quarterly revenue of $8.45 billion, falling short of analysts’ estimates of $8.53 billion and marking a 2% year-over-year decrease. However, the company was quick to point out that cloud revenue increased 34% year-over-year. Although the company seems to be successfully transitioning into a cloud-based infrastructure, the figures in the report revealed it has been hit hard by the strengthening U.S. dollar. Despite the slowed profit, analyst Daniel Ives of FBR Capital maintained an Outperform rating on the company with a $44 price target. Ives summarized, “Overall, despite a mixed bag of results over the past year, we believe Oracle remains laser focused on reaccelerating top-line growth as it heads into F2Q16/FY16, with Oracle 12c, fast-growing cloud offerings (e.g., SaaS, PaaS, IaaS), and an impressive set of engineered systems all at the forefront of the company’s growth opportunities.” As of this writing, TipRanks has polled 12 analysts who are bullish on ORCL and 8 who are staying on the sidelines. The average 12-month price target between these 20 analysts is $45.76, marking a 20% potential upside from current levels.

Click here to view Daniel Ives’ past rating history and performance.

NVIDIA Corporation (NASDAQ:NVDA) spiked 2.16% to $23.60 after analyst Mark Lipacis of Jefferies upgraded the technology company from Hold to Buy and increased his price target from $23 to $30. In the long-term, the analyst believes that two-thirds of the company’s revenue is “exposed to secular growth trends in PC gaming (56% of revs); Auto (6%) and Accelerated Computing in the Cloud (6%).” For the near-term, Lipacis thinks the company will benefit “from a PC restock, and view it as an option on the nascent Virtual/Augmented Reality (VR/AR) market, with the potential for P/E expansion as Oculus, HTC and Microsoft ship products starting in 1Q16.” Out of the 16 analysts polled by TipRanks in the last 3 months, 7 are bullish on Nvidia, 8 are on the sidelines and 1 is bearish. The average 12-month price target for the stock is $24.43, marking a nearly 6% potential upside from where the stock last closed.

Click here to view Mark Lipacis’ past rating history and performance.